julnichols / iStockphoto.com
Parallel importation of pharmaceuticals in the EU has, for a long time, raised many issues. National constraints require the parallel importer to modify the presentation of the products in order to comply with national laws, and the trademark owner has tried to make use of such alteration to oppose the commercialisation of the goods that were escaping its distribution network in that way.
If you have already subscribed please login.
If you have any technical issues please email tech support.
France jurisdiction report, parallel importers, Aurélia Marie, packaging, pharmaceuticals, labelling, distribution, medical use, commercialiation, brand
